Autolus Therapeutics Stock Buy Hold or Sell Recommendation
| AUTL Stock | USD 4.21 0.27 6.03% |
Given the investment horizon of 90 days and your way above-average risk tolerance, our recommendation regarding Autolus Therapeutics is 'Strong Sell'. Macroaxis provides Autolus Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding AUTL positions. The advice algorithm takes into account all of Autolus Therapeutics' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Autolus Therapeutics' buy or sell advice are summarized below:
Real Value 5.04 | Target Price 8.2 | Hype Value 4.39 | Market Value 4.21 | Naive Value 4.22 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Autolus Therapeutics given historical horizon and risk tolerance towards Autolus Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Autolus Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Autolus |
Execute Autolus Therapeutics Buy or Sell Advice
The Autolus recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Autolus Therapeutics. Macroaxis does not own or have any residual interests in Autolus Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Autolus Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Autolus Therapeutics Trading Alerts and Improvement Suggestions
| Autolus Therapeutics generated a negative expected return over the last 90 days | |
| Autolus Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 1.7 M. Net Loss for the year was (208.38 M) with loss before overhead, payroll, taxes, and interest of (130.86 M). | |
| Autolus Therapeutics currently holds about 216.44 M in cash with (145.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38. | |
| Autolus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 18.0% of the company shares are held by company insiders | |
| Latest headline from globenewswire.com: Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 |
Autolus Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Autolus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Autolus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Autolus Therapeutics Returns Distribution Density
The distribution of Autolus Therapeutics' historical returns is an attempt to chart the uncertainty of Autolus Therapeutics' future price movements. The chart of the probability distribution of Autolus Therapeutics daily returns describes the distribution of returns around its average expected value. We use Autolus Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Autolus Therapeutics returns is essential to provide solid investment advice for Autolus Therapeutics.
| Mean Return | -0.39 | Value At Risk | -5.89 | Potential Upside | 5.94 | Standard Deviation | 3.90 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Autolus Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Autolus Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Autolus Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Autolus Therapeutics backward and forwards among themselves. Autolus Therapeutics' institutional investor refers to the entity that pools money to purchase Autolus Therapeutics' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Schroder Investment Management Group | 2023-12-31 | 1.7 M | Affinity Asset Advisors, Llc | 2023-12-31 | 1.6 M | Laurion Capital Management Lp | 2023-09-30 | 1.5 M | Blackrock Inc | 2023-12-31 | 1.4 M | Fred Alger Management, Llc | 2023-12-31 | 1.4 M | Walleye Trading Advisors, Llc | 2023-12-31 | 850.2 K | Alphabet Inc | 2023-12-31 | 698.3 K | Lgt Capital Partners Ltd. | 2023-12-31 | 550 K | Ubs O'connor Llc | 2023-12-31 | 538.8 K | Syncona Portfolio Ltd. | 2023-12-31 | 21.3 M | Blackstone Inc | 2023-12-31 | 20.5 M |
Autolus Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (29.5M) | (57.3M) | 156.6M | 72.1M | (143.2M) | (28.1M) | |
| Depreciation | 645K | 5.7M | 8.5M | 7.4M | 6.6M | 612.8K | |
| Capital Expenditures | 4.4M | 14.7M | 8.9M | 10.8M | 11.0M | 4.2M | |
| Net Income | (20.6M) | (142.1M) | (142.1M) | (148.8M) | (208.4M) | (21.7M) | |
| End Period Cash Flow | 217.6M | 154.1M | 310.7M | 382.8M | 239.6M | 206.9M | |
| Change To Netincome | 9.7M | 17.3M | 11.6M | 25.1M | 11.2M | 13.5M | |
| Investments | (14.7M) | (8.9M) | (10.8M) | (11.0M) | (9.9M) | (10.4M) | |
| Free Cash Flow | (132.4M) | (126.7M) | (123.1M) | (156.6M) | (140.9M) | (148.0M) | |
| Other Non Cash Items | (1.5M) | 1.8M | 13.4M | 45.7M | 52.6M | 55.2M |
Autolus Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Autolus Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Autolus Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Autolus stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.49 | |
β | Beta against NYSE Composite | 0.99 | |
σ | Overall volatility | 3.93 | |
Ir | Information ratio | -0.13 |
Autolus Therapeutics Volatility Alert
Autolus Therapeutics exhibits very low volatility with skewness of 0.01 and kurtosis of 0.02. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Autolus Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Autolus Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Autolus Therapeutics Fundamentals Vs Peers
Comparing Autolus Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Autolus Therapeutics' direct or indirect competition across all of the common fundamentals between Autolus Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Autolus Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Autolus Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Autolus Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Autolus Therapeutics to competition |
| Fundamentals | Autolus Therapeutics | Peer Average |
| Return On Equity | -1.02 | -0.31 |
| Return On Asset | -0.25 | -0.14 |
| Operating Margin | (103.37) % | (5.51) % |
| Current Valuation | 1.2 B | 16.62 B |
| Shares Outstanding | 265.93 M | 571.82 M |
| Shares Owned By Insiders | 18.03 % | 10.09 % |
| Shares Owned By Institutions | 53.55 % | 39.21 % |
| Number Of Shares Shorted | 4.17 M | 4.71 M |
| Price To Earning | (19.33) X | 28.72 X |
| Price To Book | 11.98 X | 9.51 X |
| Price To Sales | 786.19 X | 11.42 X |
| Revenue | 1.7 M | 9.43 B |
| Gross Profit | (130.86 M) | 27.38 B |
| EBITDA | (188.46 M) | 3.9 B |
| Net Income | (208.38 M) | 570.98 M |
| Cash And Equivalents | 216.44 M | 2.7 B |
| Cash Per Share | 2.38 X | 5.01 X |
| Total Debt | 52.97 M | 5.32 B |
| Debt To Equity | 0.08 % | 48.70 % |
| Current Ratio | 7.29 X | 2.16 X |
| Book Value Per Share | 0.64 X | 1.93 K |
| Cash Flow From Operations | (145.59 M) | 971.22 M |
| Short Ratio | 3.59 X | 4.00 X |
| Earnings Per Share | (1.20) X | 3.12 X |
| Target Price | 10.69 | |
| Number Of Employees | 463 | 18.84 K |
| Beta | 1.93 | -0.15 |
| Market Capitalization | 1.19 B | 19.03 B |
| Total Asset | 375.38 M | 29.47 B |
| Retained Earnings | (878.56 M) | 9.33 B |
| Working Capital | 230.56 M | 1.48 B |
| Current Asset | 102.22 M | 9.34 B |
| Current Liabilities | 6.46 M | 7.9 B |
Autolus Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Autolus . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.94 | |||
| Day Median Price | 4.21 | |||
| Day Typical Price | 4.21 | |||
| Price Action Indicator | (0.14) | |||
| Period Momentum Indicator | (0.27) | |||
| Relative Strength Index | 38.68 |
About Autolus Therapeutics Buy or Sell Advice
When is the right time to buy or sell Autolus Therapeutics? Buying financial instruments such as Autolus Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2020 | 2021 | 2022 | 2024 (projected) | Other Current Liabilities | 150K | 40.8M | 44.7M | 2.2M | Total Assets | 405.6M | 490.3M | 375.4M | 279.3M |
Use Investing Ideas to Build Portfolios
In addition to having Autolus Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Real Estate Thematic Idea Now
Real Estate
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Real Estate theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Autolus Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Autolus Stock analysis
When running Autolus Therapeutics' price analysis, check to measure Autolus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Autolus Therapeutics is operating at the current time. Most of Autolus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Autolus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Autolus Therapeutics' price. Additionally, you may evaluate how the addition of Autolus Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets |
Is Autolus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.20) | Revenue Per Share 0.01 | Quarterly Revenue Growth (1.00) | Return On Assets (0.25) | Return On Equity (1.02) |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.